PO.CL07.02 · 临床研究
腹腔镜分诊的晚期卵巢癌中应答的分子决定因素
Molecular determinants of response in laparoscopically triaged advanced ovarian cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:高级别浆液性卵巢癌(HGSC)是最致命的妇科恶性肿瘤,其特征为基因组不稳定、广泛的腹膜播散,以及尽管初始对化疗敏感却仍频繁复发。初次手术时的完全肉眼切除(CGR)是最强的生存预测因子,然而它并不总是可以实现。传统影像学常常低估疾病负荷,且缺乏可靠的手术和化疗应答的分子预测因子。为解决这一问题,我们对在腹腔镜评分程序中获得的肿瘤进行了多组学分析,这些程序将患者分诊至初次肿瘤减灭手术(pTRS)或新辅助化疗(NACT)后行间隔性肿瘤减灭手术(iTRS)。
方法:从40名患者中收集治疗前新鲜冷冻肿瘤样本,分为四组:pTRS-CGR、pTRS-R1(肉眼残留病灶)、iTRS-CGR和iTRS-R1。进行批量RNA测序和多重定量蛋白质组学以表征转录组和蛋白质组特征。整合的蛋白质基因组学分析确定了与治疗结局相关的一致分子特征。这些发现在一个采用相同方案治疗的30名HGSC患者的独立多组学队列中得到了验证。
结果:实现pTRS-CGR的患者具有最有利的总生存期(OS)(中位OS 87.5个月),而iTRS-R1的结局最差(中位OS 22.9个月)。多组学整合揭示了各应答组之间不同的表达特征。与其他组相比,iTRS-R1肿瘤中共有73种蛋白和229个转录本显著上调,具有很强的蛋白质组-转录组一致性(Spearman Rho=0.837,P<1E-4)。通路分析显示,pTRS-CGR肿瘤中富集了初级纤毛形成和细胞锚定,而iTRS-R1肿瘤则表现出氧化磷酸化、线粒体代谢和应激适应性信号的激活。值得注意的是,EEF2K(真核延伸因子2激酶)——能量守恒和应激反应的关键调节因子——在iTRS-R1肿瘤中显著过表达。验证证实,在残留病灶负荷较高的NACT不良应答者中EEF2K升高。
结论:腹腔镜分诊有效地对晚期HGSC进行分层以实现最佳手术管理,其中pTRS-CGR取得最佳生存结局。多组学分析强调代谢重编程是不良应答者的标志,并确定EEF2K为潜在的预后生物标志物和治疗靶点。这些数据支持以生物标志物为导向的方法来改善晚期卵巢癌的预后。
查看英文原文 English abstract
BACKGROUND: High-grade serous ovarian cancer (HGSC) is the most lethal gynecologic malignancy, marked by genomic instability, extensive peritoneal spread, and frequent recurrence despite initial chemosensitivity. Complete gross resection (CGR) at primary surgery is the strongest predictor of survival, yet it is not always achievable. Conventional imaging often underestimates disease burden and reliable molecular predictors of surgical and chemotherapeutic response are lacking. To address this, we performed a multi-omic analysis of tumors obtained during laparoscopic scoring procedures that triaged patients to primary tumor reductive surgery (pTRS) or neoadjuvant chemotherapy (NACT) followed by interval tumor reductive surgery (iTRS).
METHODS: Pre-treatment fresh-frozen tumor samples were collected from 40 patients across four groups: pTRS-CGR, pTRS-R1 (gross residual disease), iTRS-CGR, and iTRS-R1. Bulk RNA sequencing and multiplexed quantitative proteomics were performed to characterize transcriptomic and proteomic profiles. Integrative proteogenomic analyses identified concordant molecular signatures associated with treatment outcomes. Findings were validated in an independent multi-omic cohort of 30 HGSC patients treated with identical protocols.
RESULTS: Patients achieving pTRS-CGR had the most favorable overall survival (OS) (87.5 months, median OS), whereas iTRS-R1 had the poorest outcome (22.9 months, median OS). Multi-omic integration revealed distinct expression signatures across response groups. A total of 73 proteins and 229 transcripts were significantly upregulated in iTRS-R1 tumors compared to others, with strong proteomic-transcriptomic concordance (Spearman Rho=0.837, P<1E-4). Pathway analysis showed enrichment for primary cilium formation and cell anchoring in pTRS-CGR tumors, while iTRS-R1 tumors exhibited activation of oxidative phosphorylation,
mitochondrial metabolism, and stress-adaptive signaling. Notably, EEF2K (Eukaryotic elongation factor 2 kinase), a key regulator of energy conservation and stress response, was markedly overexpressed in iTRS-R1 tumors. Validation confirmed elevated EEF2K in poor NACT responders with higher residual disease burden.
CONCLUSION: Laparoscopic triage effectively stratifies advanced HGSC for optimal surgical management, with pTRS-CGR achieving the best survival outcome. Multi-omic analyses highlight metabolic reprogramming as a hallmark of poor responders and identify EEF2K as a potential prognostic biomarker and therapeutic target. These data support biomarker-driven approaches to improve outcomes in advanced ovarian cancer.
利益披露 Disclosure
S. Corvigno, None..
N. W. Bateman, None..
A. Asare, None..
C. Tian, None..
J. Yao, None..
S. Cronin, None..
J. Ogata, None..
T. Abulez, None..
K. A. Conrads, None..
B. L. Hood, None..
J. Celestino, None..
N. D. Fleming, None..
K. M. Darcy, None..
A. A. Jazaeri, None..
S. N. Westin, None..
C. Tarmey, None..
T. P. Conrads, None..
G. L. Maxwell, None..
S. Lee, None..
A. K. Sood, None.